Top

Published in:

01-12-2012 | Short Commentary

Psoriasis during natalizumab treatment for multiple sclerosis

Authors: Jorge Millán-Pascual, Laura Turpín-Fenoll, Pablo Del Saz-Saucedo, Ignacio Rueda-Medina, Santiago Navarro-Muñoz

Published in: Journal of Neurology | Issue 12/2012

Abstract

Beta-interferon therapy is known to trigger psoriasis, but this effect has not been previously reported for other multiple sclerosis treatments, such as natalizumab. The following is a case report. A 31-year-old woman affected by psoriasis and relapsing–remitting multiple sclerosis suffered a severe worsening of psoriasis symptoms during natalizumab treatment and acquired a drug-resistant course. This case suggests that aggravation of psoriasis might be a rare side effect of natalizumab, and that clinicians should be aware of the possibility of paradoxical activation of autoimmune diseases during its treatment.

Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3(1):32–38PubMed

Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233–240PubMedCrossRef

Webster GF, Knobler RL, Lublin FD et al (1996) Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patient with multiple sclerosis. J Am AcadDermatol 34:365–367CrossRef

Lopez-Lerma I, Iranzo P, Herrero C (2009) New-onset psoriasis in a patient treated with interferon beta 1-a. Br J Dermatol 160:716–717PubMedCrossRef

Navne JE, Hedegaard U, Bygum A (2005) Activation of psoriasis in patients undergoing treatment with interferon beta. UgeskrLaeger 167:2903–2904

La Mantia L, Capsoni F (2010) Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 31:337–339PubMedCrossRef

Kwok T, Loo J, Guenther L (2010) Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg 14(4):151–155PubMed

Ramagolapan SV, Dyment DA, Valdar W et al (2007) Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 6:604–610CrossRef

Ganesvaran G, Greer JM, Pender MP (2009) Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Mult Scler 15:763–766PubMedCrossRef

10.

Ghoreschi K, Brück J, Kellerer C, Deng C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291–2303PubMedCrossRef

11.

Axtell RC, Raman C, Steinman L (2011) Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol 32(6):272–277PubMedCrossRef

12.

Borchers AT, Leibushor N, Cheema GS, Naguwa SM et al (2011) Immune-mediated adverse effects of biological used in the treatment of rheumatic diseases. J Autoimmunity 37:273–288CrossRef

13.

Tristano G (2010) Neurological adverse events associated with anti-tumor necrosis factor alphatreatment. J Neurol 257(9):1421–1431PubMedCrossRef

14.

Rivera-Nieves J, Gorfu G, Ley K (2008) Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 14:1715–1735PubMedCrossRef

15.

Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the nervous system. J Neuroimmunol 98:77–88PubMedCrossRef

16.

Bjursten M, Bland PW et al (2005) Long-term treatment with anti-alpha4 integrin antibodies aggravates colitis in G alpha i2-deficient mice. Eur J Immunol 35(8):2274–2283PubMedCrossRef

17.

Monnier-Murina K, Du Thanh A, Merlet-Abrans S et al (2009) Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical immune reaction? Dermatology 219(1):89–90PubMedCrossRef

18.

Durox H, Sparsa A, Lonstand-Ratti V et al (2008) Efalizumab-induced lupus-like syndrome. Acta Derm Venereol 88:270–271PubMed

19.

Lisotti A, Azzaroli F, Brillanti S et al (2012) Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis 44(4):356–357PubMedCrossRef

Title: Psoriasis during natalizumab treatment for multiple sclerosis
Authors: Jorge Millán-Pascual
Laura Turpín-Fenoll
Pablo Del Saz-Saucedo
Ignacio Rueda-Medina
Santiago Navarro-Muñoz
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 12/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6713-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Psoriasis during natalizumab treatment for multiple sclerosis

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis

Clinical and imaging features of the room tilt illusion

Vitamin D levels in Hispanics with multiple sclerosis

Auditory pathway changes mirror overall disease progress in individuals with Friedreich ataxia

A case of multiple system atrophy with normal dopamine transporter imaging

Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders